# Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

> **NCT06807606** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Drugs Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Thiotepa
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT06807606
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06807606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06807606, "Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06807606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*